Variational Development Services offers a ligand-based small molecule generative AI service: The pharma company gives them a list of the hits and non-hits of their initial high-throughput screens. They repatriate a list of compounds with which they are supposed to be richer hits, and perhaps, with specific ADMET properties, patentability, synthesizability, etc. These compounds are then synthesized and tested by the pharma partner who then sends it through optimization, animal models, clinical, etc.





<p dir="ltr" style="line-height: 1.38; margin-top: 0pt; margin-bottom: 0pt;">